Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029360 | 0.80 | TSHR (0.43) | TSHRALDH1A1 | |
| SCHEMBL124655 | 0.80 | TSHR (0.43) | TSHRALDH1A1 | |
| SCHEMBL385253 | 0.80 | TSHR (0.43) | TSHRALDH1A1 | |
| SCHEMBL29131476 | 0.76 | TSHR (0.42) | TSHRALDH1A1 | |
| SCHEMBL3639103 | 0.73 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL5008705 | 0.72 | CCR5 (0.32) | ALDH1A1 | |
| SCHEMBL675973 | 0.71 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL15018741 | 0.71 | TSHR (0.48) | TSHRALDH1A1 | |
| Pentane SCHEMBL10676495 | 0.70 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL4837074 | 0.65 | TSHR (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110313032-A1 | COMPETITIVE INHIBITORS OF TYPE II DEHYDROQUINASE ENZYME | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2202230-A1 | Competitive inhibitors of type ii dehydroquinase enzyme | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2010-06-30 | — | — | EP | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080194887-A1 | SEPARATION OF FLUOROUS COMPOUNDS | PITTSBURGH UNIVERSITY OF - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2008-08-14 | — | — | US | disclosed |
| US-7364908-B2 | Separation of fluorous compounds | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-04-29 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1765783-A1 | SEPARATION OF FLUOROUS COMPOUNDS | UNIVERSITY OF PITTSBURGH (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006009835-A1 | SEPARATION OF FLUOROUS COMPOUNDS | UNIVERSITY OF PITTSBURGH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050283032-A1 | charging a mixture of compounds to a non-fluorous solid phase (silica gel, alumina, zirconia) and eluting with a fluorous eluting fluid (hydrofluoroalkane, a hydrofluoroether, a hydrofluoroamine, a perfluoroalkane, a perfluoroether, or a perfluoroamine) and a cosolvent: difference in fluorous nature | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-22 | — | — | US | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | TSHR 730/4885ALDH1A1 1370/4885 |
| US-20110313032-A1 | COMPETITIVE INHIBITORS OF TYPE II DEHYDROQUINASE ENZYME | DHODH, HSD17B14, NQO2 | TSHR 4710/4885ALDH1A1 413/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | TSHR 730/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.